CP and chronic myelogenous leukemia, BCR-ABL1 positive: Asciminib was discovered as a strong allosteric inhibitor of the proliferation of BCR-ABL-expressing leukemia cells with the same mechanism as GNF-2, which bind to the myristate binding site, and was approved in October 2021 by the FDA to treat adult patients with CML-CP [18,19,20].